Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment

Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Ernesto, Schinzari, Giovanni, Tortora, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387312/
https://www.ncbi.nlm.nih.gov/pubmed/32699182
http://dx.doi.org/10.1136/jitc-2020-000952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387312/
https://www.ncbi.nlm.nih.gov/pubmed/32699182
http://dx.doi.org/10.1136/jitc-2020-000952

Ejemplares similares